India Pharma 2020: Trends That Can Change Business Tempo
Executive Summary
Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.
You may also be interested in...
Four Digital Saviors Of Indian Pharma During COVID-19
From digital marketing to payment systems, electronic solutions are aiding Indian pharma to ensure business continuity during the lockdown. New guidelines are spurring the adoption of telemedicine. Digital tools are connecting companies to their distribution chains and health care professionals. While some changes are here to stay, others might not stick.
Four Digital Saviors Of Indian Pharma During COVID-19
From digital marketing to payment systems, electronic solutions are aiding Indian pharma to ensure business continuity during the lock-down. As new guidelines spur adoption of telemedicine and digital tools connect a company to its distribution chain and healthcare professionals, experts say some changes are here to stay, while others might not stick.
COVID-19 And M&A: Multiple Scenarios In Store As World Adapts
The coronavirus pandemic could dull pharma M&A activity in the short-term as companies hoard cash and prioritize core activities. But experts say stress in the system could potentially push some firms to cull surplus assets or seek financial/strategic investors, amid a generally tough funding environment. Private equity investors may also find attractive investment opportunities to pursue.